AChE

The highly selective TRK inhibitor Larotrectinib ( Vitrakvi ) is approved for the treatment of adult and pediatric cancers that...


Cemiplimab ( Libtayo ) monotherapy achieves clinically meaningful activity in patients with advanced cutaneous squamous cell carcinoma ( CSCC )...


The randomized, open-label, phase 3 KEYNOTE-426 study has demonstrated that Pembrolizumab ( Keytruda ) + Axitinib ( Inlyta ) significantly...


Final, mature progression-free survival ( PFS ) from the global phase III ALEX study of Alectinib ( Alecensa ) vs...


Previous treatment with immune checkpoint inhibitor ( ICI ) is more common in clinical practice since recent FDA-approval of 5...


Selpercatinib ( Retevmo ) is a highly selective and potent small molecule RET kinase inhibitor. Researchers have reported an update on...


This is the first randomized trial testing the addition of an oncolytic virus to an immune checkpoint inhibitor for advanced...


Treatment with checkpoint inhibitors or targeted therapy improves outcomes in patients with BRAF V600–mutant advanced melanoma; however, many patients subsequently...


Camrelizumab is a fully humanized, monoclonal antibody against PD-1. A study has assessed the efficacy and safety of Camrelizumab plus...


The role of induction therapy prior to autologous stem cell transplant ( ASCT ) in immunoglobulin light chain ( AL...



KEYNOTE-177 is a phase 3, randomized open-label study evaluating the efficacy and safety of Pembrolizumab ( Keytruda ) versus standard...


The FDA ( U.S. Food and Drug Administration ) has approved Keytruda ( Pembrolizumab ), an anti-PD-1 therapy, as monotherapy...


The FDA ( U.S. Food and Drug Administration ) has approved Koselugo ( Selumetinib ) for the treatment of pediatric...


The European Commission ( EC ) has approved Reblozyl ( Luspatercept ) for the treatment of: a) adult patients with transfusion-dependent...


Upadacitinib ( Rinvoq ) was developed as a JAK1-selective inhibitor by exploiting differences in the non-conserved domains outside the active...


The Food and Drug Administration ( FDA ) has approved an oral combination of Decitabine and Cedazuridine ( Inqovi )...


Prolonged symptom duration and disability are common in adults hospitalized with severe coronavirus disease 2019 ( COVID-19 ). Characterizing return...


The U.S. Food and Drug Administration ( FDA ) has granted accelerated approval to Tecartus ( Brexucabtagene autoleucel, formerly KTE-X19...


Based on in vitro studies, Polatuzumab vedotin + Obinutuzumab + Venetoclax ( Pola-G-Ven )may have significant anti-tumor activity in relapsed...